William Blair restated their outperform rating on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a research report report published on Monday, April 1st, AnalystRatings.com reports. William Blair also issued estimates for Atara Biotherapeutics’ Q1 2020 earnings at ($1.41) EPS, Q2 2020 earnings at ($1.41) EPS, Q3 2020 earnings at ($1.40) EPS and Q4 2020 earnings at ($1.35) EPS.
“We view the results as very promising given the high efficacy and very favorable safety profile, with no evidence of on-target, off-tumor toxicity of the CAR-T therapy . Given the strong expression of mesothelin across several tumor types, including mesothelioma (90%-plus), lung adenocarcinoma (60%-plus), triple negative breast cancer (TNBC, 35%), and pancreatic cancer (80%), the opportunity for a mesothelin- CAR-T therapy with a strong safety profile is significant.”,” the firm’s analyst wrote.
Other analysts also recently issued reports about the stock. Zacks Investment Research downgraded shares of Atara Biotherapeutics from a hold rating to a sell rating in a report on Monday, March 4th. BidaskClub downgraded shares of Atara Biotherapeutics from a buy rating to a hold rating in a report on Friday, February 22nd. ValuEngine downgraded shares of Atara Biotherapeutics from a strong-buy rating to a buy rating in a report on Tuesday, February 12th. Cowen reiterated a buy rating on shares of Atara Biotherapeutics in a report on Tuesday, February 26th. Finally, Mizuho reiterated a buy rating and set a $62.00 price target on shares of Atara Biotherapeutics in a report on Tuesday, February 26th. Three research analysts have rated the stock with a sell rating and six have given a buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of $49.00.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Tuesday, February 26th. The biotechnology company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.44). As a group, sell-side analysts forecast that Atara Biotherapeutics will post -5.99 earnings per share for the current year.
In other Atara Biotherapeutics news, insider Joe Newell sold 1,000 shares of the business’s stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $37.80, for a total value of $37,800.00. Following the completion of the sale, the insider now directly owns 33,358 shares of the company’s stock, valued at approximately $1,260,932.40. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Joel S. Marcus sold 62,590 shares of the company’s stock in a transaction that occurred on Thursday, February 28th. The stock was sold at an average price of $36.07, for a total transaction of $2,257,621.30. Following the completion of the sale, the director now directly owns 32,590 shares of the company’s stock, valued at approximately $1,175,521.30. The disclosure for this sale can be found here. Over the last three months, insiders sold 154,724 shares of company stock valued at $5,796,503. 10.60% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in ATRA. Norges Bank purchased a new stake in shares of Atara Biotherapeutics in the 4th quarter worth approximately $20,648,000. JPMorgan Chase & Co. lifted its position in shares of Atara Biotherapeutics by 35.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,202,912 shares of the biotechnology company’s stock worth $49,741,000 after purchasing an additional 315,921 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Atara Biotherapeutics by 107.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 474,973 shares of the biotechnology company’s stock worth $16,500,000 after purchasing an additional 245,832 shares during the period. Canada Pension Plan Investment Board purchased a new stake in shares of Atara Biotherapeutics in the 4th quarter worth approximately $6,673,000. Finally, BlackRock Inc. lifted its position in shares of Atara Biotherapeutics by 3.8% in the 3rd quarter. BlackRock Inc. now owns 3,490,782 shares of the biotechnology company’s stock worth $144,345,000 after purchasing an additional 126,178 shares during the period.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Story: What is total return in investing?
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.